In conclusion, we provided a systematic and comprehensive analysis of CCRCC and is the first to suggest that ITGAX, LAPTM5, and SERPINE1 might be used as biomarkers for the new clinical diagnosis and treatment of CCRCC. The gene discussed is ITGAX; the disease is nonpapillary renal cell carcinoma.